Introduction
Several attractive strategies to genetically manipulate the central nervous system may hold promise in treating a spectrum of neurological disorders, including Alzheimer's disease, Parkinson's disease and cancer.
1,2 Unfortunately, many of the gains reported in preliminary studies are tempered by the transient period of therapeutic protein expression in vivo. The significant, but limited advances in treating neurologic diseases emphasize the need for more effective CNS gene delivery systems. An ideal gene transfer approach should be minimally invasive, not induce an immune response and deliver local protein expression over extended periods of time.
Thus far, two major approaches for delivering genes to the CNS have been explored. Direct involves direct delivery of a gene to cells of the CNS usually via a viral vector. The recombinant viruses are typically replication-deficient and can undergo only one round of infection. Different viral vectors have been used including Herpes simplex virus, adeno-associated virus, lentivirus and retrovirus. 3, 4 Limiting factors include the inability to infect a large number of cells, difficulty targeting cells for infection (ie tumor cells versus normal cells), induction of an immune response against virus proteins and a lack of long-term, high level expression of cDNA.
Indirect gene transfer involves the delivery of a gene to cells in vitro followed by transplantation of those cells into the CNS. In this manner large numbers of transduced, targeted cells are delivered to a specific location at one time. However, to date successful CNS transplantation has been muted by the inability to identify an acceptable delivery cell system. An appropriate delivery cell should accommodate rapid and efficient in vitro manipulation, remain viable in the G 0 state in vivo, express high levels of the transgene after implantation 433 and, when indicated, exhibit minimal migration to maximize local transgene delivery to areas of the CNS. Furthermore, an overarching issue concerns potential tissue graft or cell implant rejection, unless donor cells and recipient are syngeneic or autologous. Fetal tissue grafts and cells derived from fetal nervous tissue have been utilized for this purpose. 5, 6 However, the widespread use of fetal-derived tissues in human studies is problematic due to ethical considerations and legislative regulations 7, 8 and relative concerns regarding allogeneic transplantation and widespread dissemination throughout the CNS. Other cell sources have included CNS progenitor cells [9] [10] [11] [12] and immortalized derived cell lines. 13, 14 The latter is limited by its proclivity toward unregulated cell growth and the former by difficulties in producing well-characterized cell populations and in isolating these cells from human donors. Grafts from non-CNS tissue have also been used, including skin fibroblasts 15 and adrenal medullary chromaffin cells. 16 Typically, only short-term survival or expression of cDNA was achieved.
In this study, we propose the use of adult non-transformed astrocytes as a surrogate cell population to deliver transgenes to the CNS. Although astrocytes have been previously utilized in this manner, they were either fetalderived or immortalized cell lines, which currently are not amenable to human protocols. In contrast, primary mature astrocytes represent a cell type which can be utilized for autologous transplantation, are readily manipulated in culture, survive for extended periods of time following transplantation and deliver transgenes to concise areas of the CNS without widespread dissemination.
Results

Adult non-transformed astrocytes in vitro
The procurement of mature astrocytes in rats followed the general brain biopsy protocols in effect for human subjects with simple adaptation for Gelfoam implantation (see Materials and methods). All rats tolerated the procedure well and functioned without deficit following surgery. Primary cell cultures were established immediately from isolated Gelfoam and approximately 2 weeks later staining with glial fibrillary acidic protein (GFAP) antibody confirmed the universal astrocyte nature of the cells (Figure 1 ). The astrocyte culture stained robustly with anti-A2B5 antibody, while control murine fibroblasts, NIH 3T3, were negative after staining with anti-A2B5 antibody (data not shown). In addition, RT-PCR was performed on RNA extracted from serial harvested astrocyte cultures and affirmed sustained high level transcriptional levels of GFAP (data not shown). Cells were expanded to large numbers (>6 × 10 6 cells) within 3 weeks after explantation without the addition of growth factors and were amenable to typical manipulations, including freezing in liquid nitrogen and thawing. Cells remained viable after contact inhibition in vitro for up to 12 months, but could be expanded after repeated cycles of trypsinization and reseeding.
After infection with replication-incompetent retrovirus, pLXCGN7, and selection in G418, approximately 60% of the polyclonal-selected astrocytes expressed enhanced green fluorescent protein (EGFP) as detected by flow cytometric analysis (Figure 2 ). Cells were subcloned, screened again for EGFP expression and then further expanded in preparation for subsequent CNS transplantation. Harvested and in vitro expanded astrocytes were used at passage number 7 for brain transplantation.
Survival of transplanted syngeneic mature astrocytes expressing EGFP
Four cohorts of syngeneic adult Fischer rats received transplants of adult astrocytes. Transplantations represented four combinations of re-implanted astrocytes into brain based on astrocyte derivation and site implantation (Table 1) : striatal, deep gray matter-derived astrocytes (GMDA) into gray matter (GMDA→GM); striatal GMDA into frontal lobe white matter (GMDA→WM); frontal lobe, white matter-derived astrocytes (WMDA) into white matter (WMDA→WM); and frontal lobe WMDA into GM (WMDA→GM). Controls received intracerebral implantation with wild-type explanted adult rat astrocytes. Animals were killed at 2 weeks and then every 2 weeks for 4 months and then every month thereafter up to 8 months after transplantation. At least two animals were killed at each time-point.
Snap frozen, cryostat-prepared, thin sections of brain were examined directly by fluorescent microscopy. Thin sections were prepared without tissue fixation to preserve and optimize EGFP-generated fluorescence. Under these conditions, the unfixed, frozen tissue sections exhi- bited less detail and provided less resolution than formaldehyde-fixed, paraffin-embedded, histochemical-stained tissue under the microscope.
Levels of EGFP expression in vivo was related to astrocyte derivation and site of brain implantation, ie frontal lobe white matter or striatal gray matter (Table 1) . Transplantation combination WMDA→WM produced an intense fluorescent cast of the region corresponding to the needle track against the surrounding tissue. By contrast, brain sections from control animals exhibited only minimal autofluorescence under UV light inspection. The intense, green fluorescent signal produced by WMDA→WM indicated stable, high level EGFP expression in vivo (Figure 3) . Initially, the outline of individual cells was obscured by the confluence of fluorescence, but by week 6, microscopic resolution of individual cells was possible and typical astrocytic cytoplasmic Table 1 Survival and migration of adult rat astrocytes following brain implantation
Precise coordinates used for isolation and implantation are detailed in Materials and methods. GMDA, gray matter-derived astrocytes; WMDA, white matter-derived astrocytes; GM, striatal implantation; WM, anterior frontal lobe implantation; CC, corpus callosum. a Based on mean qualitative fluorescent microscopy assessment of persistent EGFP signal, at 8 weeks after implantation, where + is mildly intense and +++ is a very intense signal, x200. processes were identified within the needle track. This pattern was invariable from week 2 to 8 months after WMDA→WM implantation. EGFP-expressing, frontal lobe, WMDA transplanted into the striatum (WMDA→GM) survived equally well as WMDA→WM. Minimal yellow autofluorescence was noted in and surrounding the implantation site ( Figure  4a , b). In contrast, adult rat striatal, GMDA transplanted
Figure 4 Thin section photomicrographs of rat brains 8 weeks after transplantation (×200). Frontal lobe-derived rat astrocytes were infected and then implanted into the frontal lobe (a) or the striatum (b). Striatal-derived astrocytes were infected and implanted into the frontal lobe (c) or the striatum (d). Both astrocyte populations remained viable at the implantation site long term.
into the striatum (GMDA→GM) or into the frontal lobe (GMDA→WM) did not survive as well (Figure 4c, d ). Specifically, there was an overall decrease in EGFP positive cell number, as well as an increase in the amount of yellow autofluorescence in and surrounding the needle track.
Syngeneic transplantation of dead astrocyte controls
In a separate series of experiments, the relationship between in vivo cell viability and EGFP stability was determined. Successfully transduced adult rat astrocytes that expressed EGFP were ethanol-fixed and the freshly killed, fluorescing adult rat astrocytes were injected into five syngeneic Fischer adult rats. At 4 days after injection, minimal dull yellow fluorescence was detected in the needle track that persisted for 1 week, but was completely dissipated by the second week (data not shown). Thus, a definitive fluorescent green signal detected in vivo after 2 weeks after implantation was compatible only with sustained cell viability.
Migration of adult astrocytes after transplantation
Implanted astrocytes exhibited potential to migrate from the site of implantation, but migration also appeared restricted as a function of astrocyte derivation and implantation site (Table 1) . WMDA→WM invaginated within the needle track, but remained confined in situ. In contrast, WMDA→GM did not remain within the needle track. Rather, frontal lobe WMDA seeded into the dorsal portion of the anterior commissure producing a characteristic crescent-shaped pattern. Indeed, in one of six animals, frontal lobe-derived astrocytes transplanted into the striatum traversed the midline moving in an anteriorposterior direction. On the contralateral side, cells travGene Therapy eled in an anterior direction, seeding the contralateral dorsal anterior commissure in a crescent pattern. Subsequently, hematoxylin and eosin histochemical staining of these sections revealed a nearly symmetrical astrocyte implantation and migration appearance ( Figure 5 ). The region of viable EGFP-positive astrocytes and adjacent regions exhibited very little yellow autofluorescence (Figure 4b ). Finally, rat adult, striatal GMDA→GM and GMDA→WM were observed not to migrate from the injection site, but to persist in situ.
Corpus callosum migration experiment
In a separate attempt to replicate the migratory pattern observed after WMDA implantation into the striatum, frontal lobe WMDA were transplanted directly into the corpus callosum and rats were killed at 14, 28, 35 and 56 days after injection. Astrocytes initially aggregated at the bottom of the needle track and then over time migrated medially along the corpus callosum. Progression toward the midline was markedly increased between days 14 and 28. Thereafter, further medial cell movement was not detected. Transduced cells were not identified in the contralateral cerebral hemisphere at any time point ( Figure  6 ). PCR amplification against the heterologous fused GFP-NEO R gene from DNA derived from the ipsilateral and contralateral cerebral hemispheres was performed to identify migratory cells that could have escaped fluorescent microscope detection. Positive signal amplification was found, as expected, from DNA derived from the ipsilateral side of injection, but not from DNA derived from the hemisphere contralateral to the injection site (data not shown). 
Proliferative capacity of transplanted adult astrocytes
Thin sections from rats receiving adult astrocyte transplants were stained to determine if cells proliferated shortly after implantation and for extended periods thereafter. To distinguish between transplanted astrocytes and endogenous CNS cells, double immunohistochemical staining was conducted using anti-EGFP and antiproliferating cell nuclear antigen (PCNA) antibodies. At 7 days after implantation, adult astrocytes staining positive for EGFP were positive for PCNA (Figure 7) . Cells immediately surrounding the EGFP-positive adult astrocytes did not stain for PCNA. This result was universally observed for all implantation scenarios studied (GMDA→WM, GMDA→GM, WMDA→GM, WMDA→ WM). Furthermore, at 8 weeks after implantation, virtually all cells staining with anti-EGFP antibody remained positive for PCNA, and no adjacent EGFPnegative, endogenous cell was PCNA-positive. Again, this observation was found for all four transplantation combinations ( Figure 7) . However, by 4 months after implantation, EGFP-positive cells no longer stained positive for PCNA. Similarly, at 6 and 8 months after implantation EGFP-positive cells did not exhibit proliferative activity using either anti-PCNA antibody or an alternative antibody for cell proliferation, anti-Ki-67 (data not shown).
Discussion
Delivery of neurotrophic factors, growth inhibitory factors and cytokines has been shown to be of potential clinical benefit in treating several animal models of neurological diseases. [1] [2] [3] 17 However, many proteins cannot be delivered readily across the blood-brain barrier with high efficiency using traditional methodology. Furthermore, under certain circumstances very restricted anatomical delivery may be preferable in order to avoid potential toxicity from widespread CNS exposure. Efficient transfer and directed, prolonged expression of genetic information safely into the CNS could facilitate the study of pathogenic mechanisms fundamental to the development of disease and might provide an unparalleled opportunity to design new treatment modalities.
Surrogate cell transplantation has been proposed as a means to deliver long-term expression of potentially therapeutic proteins to specific sites in the CNS. Primary cell cultures of fetal and adult astrocytes have demonstrated the ability to express tyrosine hydroxylase and Gene Therapy nerve growth factor in vivo. 6, 11, 12 CNS progenitor cells, immortalized astrocytes and fetal tissue-derived astrocytes have all been utilized to this end, but extensive migration throughout the CNS has been observed following brain transplantation. [1] [2] [3] 17 Another overarching issue concerns the potential development of a host-versustissue/cell implant rejection unless donor cells and recipient are syngeneic or autologous. CNS progenitor cells, immortalized astrocytes and fetal tissue-derived astrocytes are currently only available for allogeneic transplantation.
Another impediment to gene therapy protocols involves the relatively short-term transgene expression and eventual loss of grafted cells that has been observed.
Figure 7 Dual staining of thin sections from rats receiving frontal lobe-derived astrocytes expressing EGFP. Photomicrographs in the right column represent staining with anti-PCNA antibody rhodamine conjugated second antibody (×200). Positively staining cells appear red. Photomicrographs in the left column represent the identified sections that were subsequently stained with anti-EGFP antibody and developed with DAB/nickel chloride. Positive cells appear black. Only EGFP-positive cells stain for PCNA at 2 and 8 weeks after implantation. Cells at 4 months after implantation lose positive staining for PCNA suggesting that they have entered the G 0 state.
For example, fibroblasts expressing high levels of tyrosine hydroxylase or ␤-galactosidase in vitro exhibited an approximately 70% decrease in expression 4 weeks after implantation. 18 Thereafter, even though gene expression was coupled to a strong viral promoter, levels dropped so low that the procedure was no longer deemed therapeutically useful. Several mechanisms may instigate progressive transplanted cell loss and include host-versusgraft reactions and other immune-mediated responses that induce necrosis or apoptosis of the implanted cells. Alternatively, the transplanted cells may not survive due to lack of appropriate trophic factors. 19 This study provides compelling evidence that transplantation of genetically manipulated adult, nontransformed astrocytes may serve as an effective means to deliver focal gene expression to the CNS in an autologous manner. The results indicate that in the rat, mature adult brain-derived astrocytes can be acquired safely, expanded in culture to large numbers, maintained in culture for more than 12 months, successfully genetically transduced by infection with recombinant amphotrophic retrovirus and then transplanted. The transduced, mature astrocytes displayed long-term EGFP-Neo R expression in vitro for extended time periods (>12 months). More importantly, adult astrocytes were transplanted into the brains of syngeneic rats and found to persist in a viable state while maintaining transgene expression for at least 8 months.
439
The considerable survival time of the transplanted syngeneic adult astrocytes may reflect the natural aptitude for astrocytes to remain viable in the nervous system. Astrocytes are both plentiful and distributed diffusely throughout the CNS. Trophic factors necessary for their growth and survival are very likely fairly ubiquitous. 20, 21 Thus, the mature adult astrocytes were transplanted into an environment that was naturally conducive to their survival with little adaptive adjustment required. The degree of success may also be due in part to support rendered by endogenous brain astrocytes. Astrocytes may be induced to respond to injury, proliferate and become part of the repair process in the CNS. Therefore, as a natural consequence of cell injection, endogenous astrocytes surrounding the needle track injury may have contributed to increased initial survival and even proliferation of engrafted adult astrocytes in a paracrine manner, through the release of astrocyte-specific growth factors, including ciliary neurotrophic factor. 22 Beyond persistence of gene expression and viability, adult astrocytes possess several pertinent characteristics including the ability to undergo controlled proliferation upon transplantation and to remain at the site of implantation. Cell attrition after transplantation is significant and an important problem in surrogate cell transplantation. It has been documented that approximately 95% of cells are lost using the procedure for transplantation described here. 23 Consequently, low level cell survival results in a decrease in the overall level of transgene being supplied. Cells, which retain a controlled capacity to proliferate after implantation, but which do not undergo transformation, may mitigate this problem. Transduced, adult astrocytes expressing EGFP appear to undergo a limited number of cell divisions after transplantation as evidenced by persistent PCNA positivity several months following implant. However, it also appears that cells eventually convert to an apparent G 0 state. The limited proliferative activity therefore may compensate for the significant initial cell loss following transplantation. Furthermore, among the limited number of experiments performed, no rat displayed evidence of a neoplastic or transformed state after receiving genetically modified adult rat astrocytes, suggesting that the cells eventually settle into a quiescent state and that risk of transformation is relatively very low.
Under certain clinical conditions the concise focal expression of a transgene may be preferable to disseminated expression. For example, the precise delivery of enzyme, neurotransmitter or neurotrophic factor, via modified adult astrocytes to cells of the striatum may provide a direct method to supplement deficient neurons in Parkinson's disease. Likewise, transplantation of adult astrocytes expressing pro-inflammatory cytokines or antiangiogenic factors into a primary brain tumor could expose neoplastic cells to a higher concentration of elaborated transgene product and thereby limit potential side-effects to surrounding normal brain parenchyma. Other surrogate cells currently utilized for CNS transplantation migrate extensively after transplantation. Most notably, immortalized astrocytes and fetal astrocytes have demonstrated migration of up to 0.75 mm/day. 24 In general, the genetically modified adult astrocytes that were developed and utilized in these studies, exhibited limited tendency to migrate from the site of implantation ( Figure 8 , Table 1 ). In one WMDA→GM transplanGene Therapy tation experiment, migration was noted across the anterior commissure to the contralateral hemisphere. It is possible that adult astrocytes have a limited capacity to migrate along white matter tracts, such as the corpus callosum or anterior commissure. Mature adult astrocytes appear to be limited spatially and temporally, since astrocytes implanted into the corpus callosum did not reach the midline, but did migrate a short distance medially. The extent of migration rapidly plateaued and migratory distance did not significantly increase after 28 days. Chu et al 25 has reported that fetal astrocytes only migrated if they were induced to differentiate in vitro and then implanted into the corpus callosum, supporting the presence of spatial and temporal specific migration cues.
Figure 8 Localization of astrocytes after transplantation. Dark arrows indicate needle placement for injection. Green areas indicate transplanted EGFP expressing astrocytes. (a) Implantation of astrocytes into the anterior frontal lobe resulted in cells surviving at the site of implantation. (b) Astrocytes implanted into the striatum seeded at the bottom of the needle tract immediately dorsal to the nucleus accumbens. (c) One animal receiving an implant into the striatum demonstrated a migratory pattern. EFGP expressing astrocytes were identified both ipsalateral and contralateral to the injection site (left schematic). Posterior sections demonstrated EGFP-positive astrocytes in the anterior commisure crossing the midline (right schematic). (d) Astrocytes implanted into the corpus
The surrogate astrocyte delivery system presented in this study has several important advantages for gene transfer to the CNS. First, the transplanted cells were syn-geneic and complications from immune-mediated graft rejection did not occur. This investigation lays the foundation for use of autologously transplanted astrocytes, and it is anticipated that an autologous system likewise will avoid potential graft rejection problems. Second, although mature adult astrocytes were acquired by an invasive neurosurgical procedure, the method is relatively safe and easily performed and may be readily adapted for harvesting adult human astrocytes and can be coupled to current CNS biopsy procedures. While brain biopsy is not without risk, morbidity and mortality are significantly lower than that associated with other invasive brain procedures, including temporal lobectomy and cortical resections, which recently have been used to obtain adult human astrocytes. 26 Third, the in vitro process of expansion, infection and transduction of mature adult astrocytes was gentle, safe and easily performed and lends itself to Good Manufacturing Protocol. Finally, transplantation of transduced astrocytes into the CNS resulted in sustained viability and long-term, focal expression of the heterologous gene. In the rat system, optimal astrocyte cultures for recombinant retroviral infection were attained within 2 to 4 weeks after harvesting. Further selection to achieve a high expressing polyclonal adult astrocyte population required only an additional 4 to 6 weeks of culture time. Assuming human cells will be amenable to similar manipulations, reimplantation of modified autologous astrocytes would be available for administration to the donor/host within 2 to 3 months after harvest. This timetable is realistic and compatible with the development of future therapies for progressive CNS diseases, including cancer and degenerative disorders.
Materials and methods
Harvesting adult non-transformed rat astrocytes
The harvesting of nontransformed adult rat astrocytes was conducted according to animal research protocols reviewed and approved by the Animal Subcommittee, Roswell, Park Cancer Institute, Buffalo, NY, USA. All aspects of animal care were in accordance with NIH guidelines. All rats and rat astrocytes used in this study were adult Fischer 344 obtained from Harlan SpragueDawley (Indianapolis, IN, USA). Adult rats were 3 to 4 months of age and weighed 200 to 300 g. Astrocytes were obtained by surgical implantation of gelatin sponge (Gelfoam; Upjohn, Kalamazoo, MI, USA) into deep gray matter or white matter of adult Fischer rats. 27, 28 A scalp incision was made in four anesthetized rats followed by the formation of a burr hole. Established coordinates (see Materials and methods, Astrocyte Transplantation subsection, for exact sterotactic coordinates) enabled a 20-gauge cannula mounted in a micromanipulator to be directed to the predetermined coordinates. The cannula was advanced with stylet in place. Eventually, the stylet was removed and deeper cannula penetration with suction allowed for the formation of a biopsy cavity. Gelfoam used was the amount sufficient to fill the distal half of the biopsy cavity in order to minimize infiltration and contamination of astrocytes from more superficial and dorsal locations. Thereafter, the incision was closed.
Three days later, the Gelfoam was removed and prepared for culture by mincing and incubation in trypsin and DNase. The treated Gelfoam was passed through a 20-m mesh and suspended in Dulbecco's modified minimal essential medium (DMEM; Gibco BRL, Grand Island, NY, USA) with 20% fetal bovine serum (FBS), and maintained at 37°C in a humidified 5% CO 2 room air incubator. The pure astrocytic composition of the cultures was confirmed by histochemical staining with anti-GFAP antibody (Dako Corp, Carpinteria, CA, USA). In addition, in order to provide further evidence of GFAP expression, RT-PCR was performed on RNA extracted from serial harvested astrocyte cultures.
Cloning of retroviral vector and harvesting of infectious supernatant
The retroviral expression vector pLXCGN was constructed by blunt-end ligation of the enhanced green fluorescent protein cDNA (Clontech, Palo Alto, CA, USA) into the mouse Moloney leukemia virus retroviral vector pLXCN upstream and in-frame with the neomycin phosphotransferase gene (Neo R ). The resulting EGFP-Neo R fusion protein is constitutively expressed and under the control of the CMV immediate-early promoter ( Figure 9 ). The packaging cell line, PA317, 29 was transfected with pLXCGN and then selected in G418. Subsequently, transduced PA317 cells were subcloned via limiting dilution and then clones were screened for EGFP expression and viral titer against NIH 3T3 target cells. A subclone, pLXCGN7, was identified that produced both high level EGFP expression and high titer viral supernatant (1 × 10 7 colony forming units/ml). The PA317 cell line transfected with pLXCGN was tested for helper virus production and was negative. The pLXCGN7 subclone was further expanded in vitro for large volume viral supernatant harvesting. High titer viral supernates were aliquoted and stored at Ϫ70°C.
Infection of adult rat astrocytes
Astrocytes were prepared for infection by plating in 25-cm 2 flasks at a concentration of 1 × 10 4 cell/cm 2 and then grown in log phase for 24 h. Viral stocks were thawed and astrocyte media (DMEM, 10% FBS) was replaced with viral supernatant after the addition of 5 g/ml protamine sulfate. Viral supernatant was removed after 12 h and replaced with astrocyte media. Twenty-four hours later 150 g/ml of G418 was added to culture to select for infected cells.
Astrocyte transplantation
Harvested, in vitro-expanded astrocytes were used at passage number 7 for brain transplantation. Confluent cells were trypsinized until they passively detached from the culture flask, washed twice in serum-free DMEM and then resuspended at a concentration of 2 × 10 7 cells/ml. These cells were immediately used for injection. When several animals received cell injections, cells were stored at 4°C between procedures. If two or more cell types were transplanted within the same time-frame for an experiment, the transplanted cell populations were alternated to control for 'time out of culture' before injection.
Adult Fischer 344 rats, 3 to 4 months of age and weighing 200 to 300 g, were anesthetized by intraperitoneal injection of ketamine hydrocholoride (80 mg/kg) and xylazine (4 mg/ml) and placed in a stereotactic frame (Kopf Instruments, Tujunga, CA, USA). A midline scalp incision was made. Access to brain parenchyma was accomplished by placement of a right-sided burr hole through the skull, 3.2 mm anterior and Ϫ3.0 mm lateral to bregma at a depth of 2.0 mm, for white matter implantation. For gray matter implantation the following coordinates were used: anterior 1.0 mm, lateral Ϫ2.0 mm relative to bregma at a depth of 5.5 mm. Transplants to the corpus callosum were performed at anterior 0.0 mm, lateral Ϫ2.0 mm relative to bregma at a depth of 3.2 mm (Figure 10 ). 1 × 10 5 transduced adult rat astrocytes were injected in a 5 l volume of serum-free media using a sterile 10 l Hamilton syringe with a No. 26S-gauge needle. After injection, the needle was left in place for 5 min and then slowly withdrawn over the next 4 min. The skin subsequently was closed with sutures.
Analyses of rat brains after transplantation
Animals were killed at 2 weeks and then every 2 weeks for 4 months and then every month thereafter up to 8 months after transplantation. At least two animals were killed at each time-point. Rats were killed by CO 2 inhalation, at various time-points and brains were entirely removed, frozen on dry ice and stored at Ϫ70°C, until they were examined. Subsequently, tissue was thawed to Ϫ20°C and nine 10-m serial sections were made with a cryostat at 200-m increments. Alternating sections were either immediately fixed in acetone or analyzed as a wet preparation and photographed under UV fluorescent microscopy.
PCR and RT-PCR detection of heterologous transplanted genes
DNA was isolated from the ipsilateral and contralateral hemispheres from thin sections shortly after death. Briefly, DNA isolation buffer was applied to slides of thin sections of brain tissue and a hemisection of brain tissue was manually lifted from the slide using a pipette tip. The DNA isolation buffer and tissue were then collected. Slides were washed twice in PBS and the procedure was repeated on the remaining contralateral hemisection. After incubation at 60°C for 1 h and two rounds of phenol chloroform precipitation, DNA was ethanol precipitated. Purity and concentration was determined using the spectrophotometer. 500 ng of DNA was subjected to PCR amplification according to the following schedule: cycling was preceded by an initial denaturation at 94°C for 5 min, then 94°C for 1 min, 55°C for 1 min, 72°C for 1 min, for 30 cycles. Reactions were carried out in 50 l total volume with final concentrations of 50 mM KCl, 1. each oligonucleotide primer and 0.5 units of Taq DNA polymerase (Gibco). Oligonucleotide primers were synthesized and purified in house. The forward primer (5' AAGATGGTGCGCTCCTGGACGTAG 3') was complementary to the 3' end of the CMV promoter sequence and the reverse primer (5' GCAGAGAA TTCGTGAACCGT 3') was complementary to the middle of the EGFP cDNA. This resulted in an expected amplicon size of 343 bp. DNA isolated from astrocytes infected with pLXCGN was used as a positive control.
